Department of Medicine, University of California, San Francisco, CA; Department of Respiratory Medicine, Alfred Hospital, Melbourne, Australia; Central Clinical School, Monash University, Melbourne, Australia.
Département de Médecine, Centre Hospitalier de l'Université de Montréal, Québec, Canada.
Chest. 2020 Jun;157(6):1506-1512. doi: 10.1016/j.chest.2019.12.018. Epub 2020 Jan 17.
Chronic hypersensitivity pneumonitis (CHP) is an immune-mediated interstitial lung disease (ILD) caused by inhalational exposure to environmental antigens, resulting in parenchymal fibrosis. By definition, a diagnosis of CHP assumes a history of antigen exposure, but only half of all patients eventually diagnosed with CHP will have a causative antigen identified. Individual clinician variation in eliciting a history of antigen exposure may affect the frequency and confidence of CHP diagnosis.
A list of potential causative exposures were derived from a systematic review of the literature. A Delphi method was applied to an international panel of ILD experts to obtain consensus regarding technique for the elicitation of exposure to antigens relevant to a diagnosis of CHP. The consensus threshold was set at 80% agreement, and median ≤ 2, interquartile range = 0 on a 5-point Likert scale (1, strongly agree; 2, tend to agree; 3, neither agree nor disagree; 4, disagree; 5, strongly disagree).
In two rounds, 36/40 experts participated. Experts agreed on 18 exposure items to ask every patient with suspected CHP. Themes included CHP inducing exposures, features that contribute to an exposure's relevance, and quantification of a relevant exposure. Based on the results from the literature review and Delphi process, a CHP exposure assessment instrument was derived. Using cognitive interviews, the instrument was revised by patients with ILD for readability and usability.
This Delphi survey provides items that ILD experts agree are important to ask in all patients presenting with suspected CHP and provides basis for a systematically derived CHP exposure assessment instrument. Clinical utility of this exposure assessment instrument may be affected by different local prevalence patterns of exposures. Ongoing research is required to clinically validate these items and consider their impact in more geographically diverse settings.
慢性过敏性肺炎(CHP)是一种由吸入性暴露于环境抗原引起的免疫介导性间质性肺疾病(ILD),导致实质纤维化。根据定义,CHP 的诊断假定有抗原暴露史,但最终诊断为 CHP 的患者中只有一半会确定致病抗原。个体临床医生在引出抗原暴露史方面的差异可能会影响 CHP 诊断的频率和信心。
从文献系统综述中得出了一系列潜在的致病暴露源。采用 Delphi 方法对ILD 专家国际小组进行了调查,以就与 CHP 诊断相关的抗原暴露的获取技术达成共识。共识阈值设定为 80%的一致性,中位数≤2,五分制李克特量表(1,强烈同意;2,倾向于同意;3,既不同意也不反对;4,不同意;5,强烈反对)的四分位距=0。
在两轮中,有 36/40 名专家参与。专家们就询问每一位疑似 CHP 患者的 18 项暴露项目达成一致。主题包括 CHP 诱导暴露、有助于暴露相关性的特征以及相关暴露的量化。基于文献综述和 Delphi 过程的结果,得出了 CHP 暴露评估工具。通过认知访谈,根据患者的ILD 情况对该工具进行了修订,以提高可读性和可用性。
这项 Delphi 调查提供了 ILD 专家一致认为在所有疑似 CHP 患者中都重要的询问项目,并为系统衍生的 CHP 暴露评估工具提供了依据。这种暴露评估工具的临床实用性可能会受到不同局部暴露模式的影响。需要开展进一步的研究,以临床验证这些项目,并考虑在更具地理多样性的环境中的影响。